PRP vs steroid for knee osteoarthritis | CMS Pain Management & Rehab

PRP for knee osteoarthritis in 2026: where the evidence stands and how to prepare for a visit at a pain clinic

Updated 2026-09-03. People comparing platelet-rich plasma with corticosteroid or nonsteroidal anti-inflammatory drug injections for knee osteoarthritis often want to know what lasts longer, what is safest, and how a clinic decides who may benefit. Below, we summarize recent randomized trials and meta-analyses, explain what the results may and may not mean for an individual evaluation, and offer practical questions you can bring to a visit at CMS Pain Management & Rehab. Throughout, we reference common outcome measures in this research, including the WOMAC index for pain, stiffness, and function and the visual analog scale for pain, without assuming any single approach will fit every case [9, 10, 11, 12].

What recent trials and reviews say about PRP vs corticosteroid or NSAID injections

A randomized controlled trial in patients with late-stage knee osteoarthritis reported that intra-articular PRP led to superior pain and function outcomes compared with intra-articular corticosteroid and NSAID injections over 6 months, based on validated tools including WOMAC and VAS, with supportive differences in serum biomarkers; results reflect one center’s protocol and population and do not guarantee similar responses elsewhere [10, 15]. In indirect-comparison research, a network meta-analysis found that combining PRP with hyaluronic acid ranked higher for pain and function than PRP alone, though indirect comparisons can be influenced by differences across trials and protocols [6]. Additional meta-analytic work has also examined PRP and HA, reporting signal for symptomatic improvement while emphasizing variability across studies [8].

Balancing newer findings with prior placebo-controlled data

Placebo-controlled evidence remains mixed. The RESTORE randomized clinical trial did not show a significant benefit of PRP over saline for knee pain or medial tibial cartilage volume at 12 months, underscoring that PRP is not uniformly superior to placebo across all protocols and populations [1, 14]. A broader network meta-analysis of intra-articular injectables suggested differences in relative long-term effectiveness among options, but methodological diversity across included studies means estimates should be interpreted carefully during shared decision-making [4].

How steroid and NSAID injections compare on time windows of effect

Systematic review data indicate that intra-articular corticosteroid injections provide clinically relevant benefit versus placebo primarily in the short term, with effects diminishing beyond the early follow-up window [5]. By contrast, several randomized trials and meta-analyses have reported PRP-associated improvements that extend into mid-term follow-up for some participants, although not all studies agree and individual response varies [9, 16, 17, 11, 12]. The randomized trial noted above suggested that PRP outperformed both corticosteroid and NSAID injections at 6 months in its cohort, again with the caveat that results are protocol- and population-dependent [10, 15].

Preparation and technique differences that influence interpretation

PRP is not a single product. Studies differ by platelet concentration, leukocyte content, activation method, injection volume, and number of injections, creating heterogeneity that complicates one-size-fits-all conclusions [11, 12]. Evidence suggests that leukocyte content may influence outcomes, and comparative analyses have explored differences between leukocyte-rich and leukocyte-poor preparations, though consistent superiority of one approach across all settings has not been firmly established [18]. When interpreting any headline result, it helps to know which PRP protocol was used, how many injections were given, and how outcomes were measured and timed [11, 12].

What these findings may mean during a clinic conversation

For an individual, the question is less “Which option wins?” and more “Which option fits my goals, risks, and timing right now?” Short-term relief needs, coexisting conditions, prior responses to injections or physical therapy, and preferences about recovery can all shape a plan. A clinician may also review cartilage status, alignment, and functional baselines to decide what to try first and how to track changes. Importantly, high-quality placebo-controlled data have reported both positive and neutral findings, so a cautious, trial-informed approach is reasonable [1, 14, 9, 16, 17]. If injections are considered, discussions often include how to integrate them with rehabilitation and activity modification to support function and mobility rather than relying on injections alone [11, 12]. Decisions about medications such as NSAIDs, anticoagulants, diabetes therapies, or others should be coordinated with the prescribing clinician; do not make any medication changes without that clinician’s guidance [11, 12].

Coverage and regulatory context to clarify before scheduling

Medicare’s current local coverage determination lists platelet-rich plasma as non-covered for musculoskeletal conditions, so many patients verify coverage and out-of-pocket costs in advance; private-plan policies vary and should be confirmed directly with the insurer [7]. PRP preparation systems are typically cleared through the 510(k) pathway as devices that concentrate blood components; this device clearance is distinct from an approval for treating knee osteoarthritis itself and does not establish clinical effectiveness for that indication [3, 13]. Clarifying these points early can prevent billing surprises and aligns expectations with the current evidence base.

Comparing common injection options: what to discuss about expectations

Corticosteroid injection: Evidence supports clinically relevant short-term improvement versus placebo, with benefits tending to wane beyond early follow-up; discussions often focus on timing around flares and individualized risk considerations [5].
PRP injection: Several randomized trials and meta-analyses report pain and function gains that may extend into mid-term follow-up for some people, while large placebo-controlled work has also shown no significant benefit over saline at 12 months; expectations should balance both signals [9, 16, 17, 11, 12, 1, 14].
NSAID injection: In a randomized trial, PRP outperformed intra-articular NSAID injection at 6 months in the studied cohort [10, 15].
Hyaluronic acid and combinations: Network meta-analytic data suggest PRP combined with hyaluronic acid can rank higher than PRP alone for pain and function, though indirect comparisons require caution due to protocol and population differences [6, 8].

Measuring change: WOMAC and VAS in routine follow-up

Many trials use the WOMAC index and the visual analog scale to track knee pain, stiffness, and function over time. If injections are considered, agreeing on specific, time-bound outcome checkpoints using these measures can help determine whether a given approach is helping with daily activities such as walking, stairs, or prolonged standing, without assuming that any one intervention will work the same way for everyone [9, 10, 11, 12].

Safety and recovery points to review before an injection

Across randomized trials and meta-analyses, intra-articular PRP has generally shown a safety profile characterized by transient post-injection soreness or swelling, with low rates of serious adverse events; corticosteroid comparators have also shown low serious-adverse-event rates in these trials, though risk profiles differ by individual and comorbidities [11, 12, 2]. Any injection can carry risks such as procedure-related pain, swelling, or infection, and your clinician will review individualized risk factors and procedural steps designed to reduce them [11, 12]. Plans for activity modification and rehabilitation after an injection should be personalized and made in coordination with the treating team [11, 12].

Questions to bring to a CMS Pain Management & Rehab visit about knee injections

Arriving with focused questions can make your visit more productive and help align options with your goals for function and mobility. The items below reflect how clinicians often evaluate fit and track change over time.

Based on my symptoms and imaging, what are the realistic goals for pain and function over the next few months, and how will we measure them using WOMAC and VAS? [9, 10, 11, 12].
Which injection options are reasonable for me right now, and how do their expected time windows of effect compare in my situation? [5, 9, 10, 16, 17].
If PRP is considered, which preparation do you use (leukocyte content, activation), how many injections are typically scheduled in your protocol, and is ultrasound guidance used? How does this align with the evidence you rely on? [11, 12, 18].
If hyaluronic acid is considered, is there a rationale for using it alone or with PRP in my case, and how will we judge benefit at defined checkpoints? [6, 8].
What rehabilitation and activity plan will accompany the injection to support mobility, and how will we adjust if I have a flare or limited response? [11, 12].
How will my other conditions be considered, such as diabetes, cardiovascular disease, or bleeding risk? For any medications, including NSAIDs, anticoagulants, or others, would you coordinate with my prescribing clinicians? I will not make changes without them [11, 12].
What are the likely out-of-pocket costs, and how does my insurance view PRP or hyaluronic acid injections? I understand Medicare’s local determination lists PRP as non-covered for musculoskeletal uses [7].
If an injection does not meet our predefined goals by the agreed timeline, what are the next steps or alternatives you would consider, and how will we document that decision? [4, 11, 12].

How our clinic approaches fit and follow-up

At CMS Pain Management & Rehab, discussions about knee osteoarthritis injections start with function: walking tolerance, stair use, work and caregiving demands, and sleep. When injections are considered, we outline what recent studies show, what remains uncertain, and how we would track change using validated measures over defined intervals. Given the mix of positive and neutral findings in the literature, we aim for shared decisions that match the person’s goals, the likely time window of effect, and the overall rehabilitation plan rather than relying on any single intervention in isolation [1, 14, 5, 9, 10, 11, 12].

FAQ

Is PRP better than a steroid shot for knee osteoarthritis?

Some randomized trials and meta-analyses suggest PRP can produce greater improvements in pain and function than corticosteroid injections beyond the early follow-up window, while a major placebo-controlled trial found no significant advantage of PRP over saline at 12 months. Individual response varies, and protocol details matter [5, 9, 16, 17, 1, 14].

How does PRP compare with NSAID injections?

In a randomized trial, the PRP group showed superior outcomes to both corticosteroid and intra-articular NSAID injections at 6 months in the studied population. Interpretation should consider that study’s protocol and population [10, 15].

How many PRP injections do people usually receive?

Protocols vary widely across studies in platelet concentration, leukocyte content, activation, and number of injections. Because there is no single standard, it helps to ask your clinician which protocol they use and how it aligns with the evidence they consider most relevant [11, 12, 18].

Does PRP rebuild or increase knee cartilage?

A placebo-controlled trial found no significant difference between PRP and saline in medial tibial cartilage volume at 12 months, so a disease-modifying effect on cartilage volume has not been established by that study’s protocol [1, 14].

Is PRP covered by insurance, and is it approved for knee osteoarthritis?

Medicare’s local coverage determination lists PRP as non-covered for musculoskeletal conditions; private-plan policies vary. PRP preparation devices are generally 510(k)-cleared for concentrating blood components, which is distinct from an approval to treat knee osteoarthritis [7, 3, 13].

Sources

When to Talk With a Clinician

For non-emergency questions, contact CMS Pain Management & Rehab to discuss your symptoms and care options with a qualified clinician. For emergency warning signs, call 911 or seek emergency care now rather than contacting the clinic.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Treatment options, risks, and eligibility vary; consult a qualified healthcare professional.

PRP for Knee Osteoarthritis: What Recent Trials Mean for a Clinic Visit